Your browser doesn't support javascript.
loading
The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.
Khadhouri, Sinan; Gallagher, Kevin M; MacKenzie, Kenneth R; Shah, Taimur T; Gao, Chuanyu; Moore, Sacha; Zimmermann, Eleanor F; Edison, Eric; Jefferies, Matthew; Nambiar, Arjun; Mannas, Miles P; Lee, Taeweon; Marra, Giancarlo; Lillaz, Beatrice; Gómez Rivas, Juan; Olivier, Jonathan; Assmus, Mark A; Uçar, Taha; Claps, Francesco; Boltri, Matteo; Burnhope, Tara; Nkwam, Nkwam; Tanasescu, George; Boxall, Nicholas E; Downey, Alison P; Lal, Asim A; Antón-Juanilla, Marta; Clarke, Holly; Lau, David H W; Gillams, Kathryn; Crockett, Matthew; Nielsen, Matthew; Takwoingi, Yemisi; Chuchu, Naomi; O'Rourke, John; MacLennan, Graeme; McGrath, John S; Kasivisvanathan, Veeru.
Afiliação
  • Khadhouri S; Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
  • Gallagher KM; Aberdeen Royal Infirmary, Aberdeen, UK.
  • MacKenzie KR; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Shah TT; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Gao C; Department of Clinical Surgery, Western General Hospital, University of Edinburgh, Edinburgh, UK.
  • Moore S; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Zimmermann EF; Freeman Hospital, Newcastle Upon Tyne, UK.
  • Edison E; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Jefferies M; Dept. of Surgery and Cancer, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Nambiar A; Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Mannas MP; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Lee T; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Marra G; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Lillaz B; Wrexham Maelor Hospital, Wrexham, UK.
  • Gómez Rivas J; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Olivier J; Torbay and South Devon NHS Foundation Trust, Torbay, UK.
  • Assmus MA; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Uçar T; Department of Urology, Whipps Cross Hospital, Barts Health NHS Trust, London, UK.
  • Claps F; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Boltri M; Morriston Hospital, Swansea, UK.
  • Burnhope T; British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
  • Nkwam N; Freeman Hospital, Newcastle Upon Tyne, UK.
  • Tanasescu G; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Boxall NE; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Downey AP; Department of Surgical Sciences, Città della Salute e della Scienza, Turin, Italy.
  • Lal AA; University of Turin, Turin, Italy.
  • Antón-Juanilla M; SanGiovanni Battista Hospital, Turin, Italy.
  • Clarke H; Department of Urology, La Paz University Hospital, Madrid, Spain.
  • Lau DHW; Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France.
  • Gillams K; Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada.
  • Crockett M; Department of Urology, Istanbul Medeniyet University, Istanbul, Turkey.
  • Nielsen M; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Takwoingi Y; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Chuchu N; University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
  • O'Rourke J; University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
  • MacLennan G; Department of Urology, Queen Alexandra Hospital, Portsmouth, UK.
  • McGrath JS; Salford Royal NHS Foundation Trust, Salford, UK.
  • Kasivisvanathan V; Doncaster Royal Infirmary, Doncaster, UK.
BJU Int ; 128(4): 440-450, 2021 10.
Article em En | MEDLINE | ID: mdl-33991045
ABSTRACT

OBJECTIVE:

To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND

METHODS:

This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries.

RESULTS:

Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001).

CONCLUSIONS:

A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ureterais / Neoplasias da Bexiga Urinária / Neoplasias Renais Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ureterais / Neoplasias da Bexiga Urinária / Neoplasias Renais Idioma: En Ano de publicação: 2021 Tipo de documento: Article